Back to News
Market Impact: 0.25
China SXT Secures $12 Million Financing Through Registered Direct Offering; Stock Down
Source: Nasdaq
Company FundamentalsCapital Returns (Dividends / Buybacks)
China SXT Pharmaceuticals entered into a definitive agreement with certain institutional investors to raise approximately $12 million through a registered direct offering. The company said the capital will support its operations; pricing and other offering terms were not provided.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.10
Ticker Sentiment
SXTC0.30
More News
- Dow Gains Over 100 Points; Delta Air Lines Shares Fall After Q3 Results
- The world needs Ukraine’s grain. Its farmers are running out of reasons to plant
- Why is the Chinese stock market missing the AI rally
- Tesla drops 'Full Self-Driving' brand name in Europe after regulator pushback
- Why is T-Mobile stock tumbling today?
- SpaceX makes big move into wireless. These once 'obsolete' tech stocks could benefit
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- AllMind Discusses Ontario's AI Economy with Minister Stephen Crawford and Supply Ontario CEO James Wallace
- AI Research Tools for SEDAR+, UK and ASX Filings